FY2026 Earnings Forecast for FDMT Issued By Leerink Partnrs

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Analysts at Leerink Partnrs issued their FY2026 earnings per share estimates for shares of 4D Molecular Therapeutics in a note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar anticipates that the company will post earnings per share of ($3.82) for the year. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share.

FDMT has been the topic of several other research reports. Royal Bank of Canada lowered their target price on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. Leerink Partners lowered their target price on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. BMO Capital Markets lowered shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $40.00 to $15.00 in a research note on Monday, January 13th. Chardan Capital cut their price target on 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $26.71.

4D Molecular Therapeutics Stock Up 5.2 %

FDMT opened at $3.06 on Thursday. The company has a market cap of $141.68 million, a PE ratio of -1.07 and a beta of 2.89. The company has a 50-day moving average price of $3.80 and a 200 day moving average price of $5.94. 4D Molecular Therapeutics has a twelve month low of $2.24 and a twelve month high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.10).

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several large investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new position in shares of 4D Molecular Therapeutics during the fourth quarter worth about $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in 4D Molecular Therapeutics in the 4th quarter valued at approximately $50,000. PNC Financial Services Group Inc. increased its position in 4D Molecular Therapeutics by 66.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock worth $51,000 after purchasing an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in 4D Molecular Therapeutics by 5,291.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock valued at $55,000 after purchasing an additional 9,737 shares during the last quarter. Finally, Velan Capital Investment Management LP acquired a new stake in shares of 4D Molecular Therapeutics during the 4th quarter worth about $56,000. 99.27% of the stock is owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.